CD274 and sarcoma: On a similar note, therapeutic targeting of PD-L1 and PD-1 immune checkpoints, which are expressed in ~20% of pediatric sarcoma patients in EwS and OS [46,47,48,49,50,51,52], has not shown clinical efficacy [43,53,54].